240 related articles for article (PubMed ID: 18032610)
1. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.
Miner JN; Ardecky B; Benbatoul K; Griffiths K; Larson CJ; Mais DE; Marschke K; Rosen J; Vajda E; Zhi L; Negro-Vilar A
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19244-9. PubMed ID: 18032610
[TBL] [Abstract][Full Text] [Related]
2. LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.
López FJ; Ardecky RJ; Bebo B; Benbatoul K; De Grandpre L; Liu S; Leibowitz MD; Marschke K; Rosen J; Rungta D; Viveros HO; Yen WC; Zhi L; Negro-Vilar A; Miner JN
Endocrinology; 2008 May; 149(5):2080-9. PubMed ID: 18218700
[TBL] [Abstract][Full Text] [Related]
3. The search for safer glucocorticoid receptor ligands.
Rosen J; Miner JN
Endocr Rev; 2005 May; 26(3):452-64. PubMed ID: 15814846
[TBL] [Abstract][Full Text] [Related]
4. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.
Coghlan MJ; Jacobson PB; Lane B; Nakane M; Lin CW; Elmore SW; Kym PR; Luly JR; Carter GW; Turner R; Tyree CM; Hu J; Elgort M; Rosen J; Miner JN
Mol Endocrinol; 2003 May; 17(5):860-9. PubMed ID: 12586843
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis.
Koenen M; Culemann S; Vettorazzi S; Caratti G; Frappart L; Baum W; Krönke G; Baschant U; Tuckermann JP
Ann Rheum Dis; 2018 Nov; 77(11):1610-1618. PubMed ID: 29997111
[TBL] [Abstract][Full Text] [Related]
6. Classic glucocorticoids versus non-steroidal glucocorticoid receptor modulators: survival of the fittest regulator of the immune system?
De Bosscher K; Beck IM; Haegeman G
Brain Behav Immun; 2010 Oct; 24(7):1035-42. PubMed ID: 20600811
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid analogues: potential therapeutic alternatives for treating inflammatory muscle diseases.
Reeves EK; Rayavarapu S; Damsker JM; Nagaraju K
Endocr Metab Immune Disord Drug Targets; 2012 Mar; 12(1):95-103. PubMed ID: 22214335
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: selective agonists and antagonists of the glucocorticoid receptor.
McMaster A; Ray DW
Nat Clin Pract Endocrinol Metab; 2008 Feb; 4(2):91-101. PubMed ID: 18212811
[TBL] [Abstract][Full Text] [Related]
9. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects.
McMaster A; Ray DW
Exp Physiol; 2007 Mar; 92(2):299-309. PubMed ID: 17138619
[TBL] [Abstract][Full Text] [Related]
10. The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation.
Hu X; Du S; Tunca C; Braden T; Long KR; Lee J; Webb EG; Dietz JD; Hummert S; Rouw S; Hegde SG; Webber RK; Obukowicz MG
Endocrinology; 2011 Aug; 152(8):3123-34. PubMed ID: 21558312
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204
[TBL] [Abstract][Full Text] [Related]
12. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids.
Caldenhoven E; Liden J; Wissink S; Van de Stolpe A; Raaijmakers J; Koenderman L; Okret S; Gustafsson JA; Van der Saag PT
Mol Endocrinol; 1995 Apr; 9(4):401-12. PubMed ID: 7659084
[TBL] [Abstract][Full Text] [Related]
13. JTP-117968, a novel selective glucocorticoid receptor modulator, exhibits significant anti-inflammatory effect while maintaining bone mineral density in mice.
Kurimoto T; Tamai I; Nakagawa T; Miyai A; Yamamoto Y; Kosugi Y; Deai K; Hata T; Ohta T; Matsushita M; Yamada T
Eur J Pharmacol; 2021 Mar; 895():173880. PubMed ID: 33476654
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid receptor modulators CpdX and CpdX-D3 exhibit the same in vivo antiinflammatory activities as synthetic glucocorticoids.
Hua G; Zein N; Daubeuf F; Chambon P
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14191-14199. PubMed ID: 31227605
[TBL] [Abstract][Full Text] [Related]
15. [Current insights into the development of new glucocorticoid receptor ligands].
Buttgereit F; Song IH; Straub RH; Burmester GR
Z Rheumatol; 2005 Apr; 64(3):170-6. PubMed ID: 15868334
[TBL] [Abstract][Full Text] [Related]
16. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.
Vayssière BM; Dupont S; Choquart A; Petit F; Garcia T; Marchandeau C; Gronemeyer H; Resche-Rigon M
Mol Endocrinol; 1997 Aug; 11(9):1245-55. PubMed ID: 9259316
[TBL] [Abstract][Full Text] [Related]
17. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor.
Clark AR; Belvisi MG
Pharmacol Ther; 2012 Apr; 134(1):54-67. PubMed ID: 22212616
[TBL] [Abstract][Full Text] [Related]
18. Optimized glucocorticoid therapy: teaching old drugs new tricks.
Strehl C; Buttgereit F
Mol Cell Endocrinol; 2013 Nov; 380(1-2):32-40. PubMed ID: 23403055
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.
Strehl C; van der Goes MC; Bijlsma JW; Jacobs JW; Buttgereit F
Expert Opin Investig Drugs; 2017 Feb; 26(2):187-195. PubMed ID: 28043173
[TBL] [Abstract][Full Text] [Related]
20. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation.
Vandevyver S; Dejager L; Tuckermann J; Libert C
Endocrinology; 2013 Mar; 154(3):993-1007. PubMed ID: 23384835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
